Piper Sandler Reaffirms "Overweight" Rating for Sotera Health (NASDAQ:SHC)

Key Points

• Piper Sandler reaffirmed its “Overweight” rating on Sotera Health and raised its price target from $22 to $25, implying approximately 32.7% upside from the reported share price. Analysts overall rate the stock “Moderate Buy,” with a consensus target of $20.88.
• Sotera Health reported better-than-expected quarterly results, with revenue up 9.2% year over year to $321.4 million and EPS of $0.26 versus the $0.24 consensus estimate. The company also raised its 2026 outlook for revenue, adjusted EBITDA and adjusted EPS.
• Despite improved profitability and lower net leverage, investors continue to face risks from the company’s approximately $2.2 billion debt load, as well as litigation, regulatory and reputational issues related to ethylene oxide emissions.

Sotera Health (NASDAQ:SHC - Get Free Report)'s stock had its "overweight" rating reissued by stock analysts at Piper Sandler in a note issued to investors on Friday,Benzinga reports. They currently have a $25.00 price target on the stock, up from their previous price target of $22.00. Piper Sandler's price target points to a potential upside of 32.73% from the company's current price.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group started coverage on shares of Sotera Health in a report on Friday, June 5th. They issued a "buy" rating and a $20.00 target price on the stock. JPMorgan Chase & Co. raised their price objective on shares of Sotera Health from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Friday. Wall Street Zen lowered Sotera Health from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 11th. Barclays reiterated an "overweight" rating on shares of Sotera Health in a research report on Friday. Finally, UBS Group set a $19.00 price target on Sotera Health in a report on Wednesday, June 24th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $20.88.

Sotera Health Stock Performance

Shares of SHC stock traded down $0.07 during midday trading on Friday, hitting $18.84. The company had a trading volume of 1,102,288 shares, compared to its average volume of 2,867,544. The stock has a market cap of $5.37 billion, a price-to-earnings ratio of 45.94 and a beta of 1.77. The company has a debt-to-equity ratio of 3.56, a current ratio of 2.82 and a quick ratio of 2.54. The company's 50 day simple moving average is $17.07 and its 200 day simple moving average is $16.31. Sotera Health has a 52-week low of $12.94 and a 52-week high of $19.85.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.02. The firm had revenue of $321.38 million for the quarter, compared to analyst estimates of $309.70 million. Sotera Health had a net margin of 9.91% and a return on equity of 39.73%. Sotera Health's quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the firm posted $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Research analysts anticipate that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 15.36% of the company's stock.

Institutional Investors Weigh In On Sotera Health

Institutional investors and hedge funds have recently modified their holdings of the company. IFP Advisors Inc increased its position in shares of Sotera Health by 1,105.6% in the fourth quarter. IFP Advisors Inc now owns 1,495 shares of the company's stock valued at $26,000 after buying an additional 1,371 shares in the last quarter. Rothschild Investment LLC acquired a new stake in Sotera Health in the 4th quarter valued at about $27,000. Root Financial Partners LLC grew its stake in Sotera Health by 217.5% in the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company's stock valued at $30,000 after acquiring an additional 1,455 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Sotera Health by 831.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company's stock valued at $37,000 after acquiring an additional 2,935 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new position in Sotera Health during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 91.03% of the company's stock.

Key Stories Impacting Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Second-quarter revenue rose 9.2% year over year to $321.4 million, ahead of the $309.7 million consensus estimate. Adjusted EPS was $0.26, topping expectations of $0.24 and increasing from $0.20 a year earlier. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved significantly: GAAP net income increased to $53.6 million from $8.0 million, while adjusted EBITDA grew 10% and the adjusted EBITDA margin expanded to 51.6%.
• Positive Sentiment: Growth was broad-based. Sterigenics revenue increased 7.0% on a constant-currency basis, Nordion grew 16.7%, and Nelson Labs rose 5.4%. Nordion also delivered a 160-basis-point improvement in segment margin.
• Positive Sentiment: Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25% to 6.75%, adjusted EBITDA growth of 5.75% to 7.25%, and adjusted EPS of $0.95 to $1.01 versus the prior midpoint of expectations. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Balance-sheet trends improved modestly. Net leverage declined to 3.0x, within the company’s long-term target range, liquidity reached approximately $950 million, and a term-loan repricing is expected to reduce annual interest expense by about $3.5 million.
• Neutral Sentiment: The earnings call highlighted confidence in demand for Sotera Health’s mission-critical sterilization, isotope and laboratory-testing services, but future results remain dependent on supply availability, inflation, foreign exchange and execution across its business units. Sotera Health Q2 2026 Earnings Call Transcript
• Negative Sentiment: Total debt remained high at approximately $2.2 billion. Investors also continue to face litigation, regulatory and reputational risks tied to ethylene oxide emissions, while higher costs pressured Nelson Labs’ first-half segment income.

About Sotera Health

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source